Why are Most Drugs Basic: Implications in Pharmaceutical Testing by HPLC

Analyses of the global pharmacopeia show that ~70–85% of marketed drugs are basic, approximately 10–20% are acidic, and the remainder are neutral or zwitterionic.^1,2 Figure 1 illustrates the bimodal pKa distribution of marketed drugs, with one peak at pH 3–5 (acidic drugs) and a larger peak at pH 7–11 (basic drugs containing amines or other nitrogen heterocycles).

Figure 2 highlights three familiar over‑the‑counter products and their basic active pharmaceutical ingredients (APIs). This article explores why basic drugs dominate modern therapeutics and how this physicochemical property created significant challenges in silica‑based HPLC, including peak tailing and poor batch‑to‑batch reproducibility. It also chronicles the innovations that ultimately enabled robust, reproducible analysis of basic analytes using silica‑based columns with or without buffers.³

Why are Most Drugs Basic?

Paul Ehrlich’s first law of pharmacology—corpora non agunt nisi fixata (“a drug will not act unless it is bound”)—captures the central principle that drug action requires specific binding to a biological target.⁴ These targets, receptors, enzymes, transporters, and ion channels are proteins composed of acidic, basic, and neutral amino acids. Basic drugs, especially those containing amines or N‑heterocycles, offer several advantages in binding, permeability, and formulation.

Receptor Binding
Protonated basic drugs interact strongly with acidic residues on protein targets through acid–base interactions, hydrogen bonding, and π–π and cation–π interactions. These interactions often enhance affinity and selectivity.⁵

Membrane Permeability
At physiological pHs of the intestinal region (6.0–7.5) and blood (7.4), many basic drugs are partially non-ionized, enabling efficient passive diffusion across the cell membrane’s lipid bilayer and improving bioavailability.⁶

Formulation Flexibility
Most small‑molecule drugs are formulated as oral solid dosage forms with a multi‑year shelf life. Basic drugs offer greater chemical stability than acidic drugs, greater flexibility in salt‑forming options, good solubility in gastric fluid, and broad excipient compatibility.⁷

These advantages help explain why basic drugs dominate the pharmacopeia.

Implications in Pharmaceutical Testing by HPLC
Reversed‑phase chromatography (RPC) using an acidic mobile phase A (MPA) and UV detection on silica‑based columns has become the workhorse technique for pharmaceutical analysis.⁸ However, before the 1990s, silica columns exhibited severe peak tailing and poor reproducibility for basic analytes due to interactions with acidic residual silanols.

Table 1 summarizes the four major stages of technological development that resolved these issues and extended their applicability to highly water-soluble bases and to the use of low-ionic-strength mobile phases for highly basic drugs.^3,8–12

The development is divided into four stages with a rough timeline, issues, product/operating solutions, and references. MPA = mobile phase A, HILIC = hydrophilic interaction chromatography, BEH = Bridged Ethyl Hybrid, CSH = Charged Surface Hybrid, AMT PCS = Advanced Materials Technology, Positive Charged Surface.

Stage 1 (Pre-1980s) — The Traditional Sil-Gel Silica and Its Limitations
Early HPLC columns used silica produced by acidifying sodium silicate (“sil‑gel process”), yielding porous silica contaminated with metallic oxides (Na⁺, Ca²⁺, Mg²⁺, Al³⁺, Fe³⁺).^9–12 Metal ions such as Fe³⁺ and Al³⁺ activate silanols by coordinating to the silanol oxygen, increasing their acidity and forming strong interactions that lead to severe tailing of basic analytes. Because metal content from Type A silica varied widely, batch‑to‑batch reproducibility was poor, creating significant challenges for pharmaceutical quality control (QC).

To cope, pharma laboratories often purchased large quantities of columns from a single silica batch or added amine‑masking agents (such as triethylamine [TEA]) to the MPA to suppress silanol interactions. This masking strategy was pioneered by Dennis W. Hill, who used TEA to improve peak shape and assay robustness in toxicology testing of racing dogs and athletes.¹³

Stage 2 (1980s-1990s) – The Advent of High-Purity Silica
A permanent solution arrived with the shift to synthetic Type B silica, produced by sol–gel processing from high‑purity monomers such as tetraethoxysilane.^9–12 This production method eliminated most metal contaminants and dramatically improved peak symmetry and reproducibility. To the pharmaceutical QC Lab, this fundamental improvement ensures reliability in global manufacturing and method transfers.

Early high‑purity silica columns included the following:

• DuPont/Rockland/Agilent ZORBAX Rx (Jack Kirkland, who founded Rockland Technologies in 1989, which was acquired by Hewlett-Packard [Agilent] in 1997)
• GL Science Inertsil
• Merck Purospher
• The Separation Group’s Vydac (company founded by Kervin Harrison that pioneered wide‑pore silica for RPC of proteins and peptides)¹⁴
• Waters Symmetry

By the mid-1990s, Type B silica had become the industry standard, resolving the foundational issues of tailing and reproducibility.^3,12

Stage 3 (1990s-2000s) — Retention of Highly Water-Soluble Bases

The use of acidic MPAs (pH 2–4) is the default in pharmaceutical testing because they suppress silanol ionization (from Si-OH to Si-O^-) and improve peak shape for basic drugs. However, highly water‑soluble bases often show insufficient retention under these conditions.

Solutions included the following:

• Ion-pair and chaotropic agents additives³
• Intermediate coverage or polar‑end capped phases (such as Waters Atlantis T3 and HSS T3, Agilent ZORBAX SB‑AQ, YMC-Pack-ODS AQ, Shimadzu Shim-pack XR-ODS AQ, Thermo Accucore AQ)^3,10,12
• HILIC for very polar bases¹⁵
• High‑pH separations using hybrid silica (XTerra; ACQUITY BEH; Agilent Poroshell HPH; YMC TriArt, Shim-pack XR-ODS III)^3,16

Several techniques mentioned above were introduced to increase RPC retentivity, either by modifying the ionic charge of the basic analyte or by increasing the hydrophilicity of the stationary phase. One notable innovation was hydrophilic interaction chromatography (HILIC), introduced by Andrew Alpert in 1990,¹⁵ which is a complementary separation mode to RPC³ by maintaining a water layer on the hydrophilic phase while using RPC-like mobile phases.

The most significant breakthrough in pharmaceutical quality control has been the development of high-pH-compatible column phases, such as those based on hybrid silica. These allow for reliable analysis of basic drugs that are highly soluble in water, overcoming the limitations of standard silica columns, which operate over a narrower pH range of 2–8. Figure 3 shows a stability‑indicating method for opioids at pH 9.1 on a Waters XTerra MS C18, demonstrating the power of MS-compatible high‑pH gradient separations for common painkillers such as morphine and oxycodone.¹⁷

Stage 4 (>2000s) — QC Methods Without Buffers

Buffers maintain strict pH control for complex separation and introduce ions that shield acidic silanols, preventing strong interactions with protonated basic analytes and improving peak symmetry. However, many development and QC laboratories prefer simpler acidic MPAs—typically 0.1% formic acid or TFA—because they are easy to prepare and MS-compatible. Unfortunately, highly basic analytes frequently exhibit poor peak shape in low‑ionic‑strength mobile phases, where residual silanols remain active without the shielding provided by buffers. Another plausible explanation was overloading due to the mutual repulsion of charged analytes bound to the hydrophobic portion of the stationary phase, as proposed by David McCalley.¹⁸ This renewed the need for stationary-phase solutions rather than relying on high-ionic-strength mobile phase fixes.

Figure 4 illustrates this problem: four highly basic new chemical entities (NCEs) show severe tailing (“shark fin”) on a BEH C18 column using 0.05% formic acid.¹⁹ A positively charged surface phase (Cortecs C18+) eliminates this interaction, restoring peak symmetry.^19,20

Other manufacturers achieve similar silanol deactivation using surface‑protection bonding, as in Agilent Poroshell 120 HPH.^19,21

Summary and Conclusions

This article tells a two‑part story. First, it explains why basic drugs dominate modern therapeutics, drawing on principles of receptor binding, membrane permeability, and formulation science. Second, it traces the evolution of silica‑based HPLC technology, from metal‑contaminated Type A silica to high‑purity Type B silica and modern hybrid or surface‑modified materials. These innovations—improved silica purity, advanced bonding chemistries, hybrid particles, and surface‑charge technologies—have transformed the analysis of basic drugs. Today, robust, reproducible separations can be achieved using silica‑based columns with either buffered or simple acidic mobile phases.

Acknowledgments

I gratefully acknowledge the valuable technical and editorial contributions provided by Matt Mullaney (retired), Alice Krumenaker (retired from Hovione), David VanMeter of Proteome Sciences plc, Michael Heidorn of Agilent, and Tom Walter of Waters.

References

1. Manallack, D. T. The pKa Distribution of Drugs: Application to Drug Discovery. Perspect Medicin Chem 2007, 1, 25–38.
2. Charifson, P.S.; Walters, W. P. Acidic and Basic Drugs in Medicinal Chemistry: A Perspective, J Med Chem 2014. 57 (23), 9701-9717. DOI: 10.1021/jm501000a
3. Dong, M. W. HPLC and UHPLC for Practicing Scientists, 2nd Ed.; Wiley, 2019, Chapters 2, 3, 9-10.
4. Ritter, J.M.; Flower, R. J.; Henderson, G. et al. Rang & Dale’s Pharmacology, 9th Ed.; Elsevier, 2019.
5. Open Access Journals. Understanding Drug–Receptor Interactions: Unlocking the Secrets of Pharmaceutical Action. https://www.openaccessjournals.com/articles/understanding-drugreceptor-interactions-unlocking-the-secrets-of-pharmaceutical-action.pdf
6. Allen, L. V. Pharmaceutical Dosage Forms and Drug Delivery Systems, Sample Chapter. https://downloads.lww.com/wolterskluwer_vitalstream_com/sample-content/9780781779340_Allen/samples/Chapter04.pdf
7. Loftsson, T. Drug Stability for Pharmaceutical Scientists, 1^st Ed; Academic Press, 2014.
8. Guillarme D.; Dong, M. W. Newer Developments in HPLC Impacting Pharmaceutical Analysis: A Brief Review. Amer Pharm Rev 2013, 16 (4), 36-43.
9. Snyder, L. R.; Kirkland, J. J.; Dolan, J. Introduction to Modern Liquid Chromatography, 3^rd Ed.; John Wiley & Sons, 2010, Chapters 5 and 7. DOI:10.1002/9780470508183
10. Neue, U. D. HPLC Columns: Theory, Technology, and Practice; Wiley-VCH, 1997.
11. Unger, K. Porous Silica; Elsevier, 1979.
12. Majors, R. Historical Developments in HPLC and UHPLC Column Technology: The Past 25 Years. LCGC North Am 2015, 33 (11), 818–840.
13. Hill D. W.; Langner, K. J. HPLC Photodiode Array UV Detection for Toxicological Drug Analysis. J Liq Chromatogr 1987, 10 (2), 377-409. DOI: 10.1080/01483918708066724
14. Regnier, F. HPLC of Biopolymers. Science 1983, 222 (4621), 245-252.
15. Alpert, A. J. Hydrophilic-Interaction Chromatography for the Separation of Peptides, Nucleic Acids and Other Polar Compounds, J Chromatogr A 1990, 499, 177-196. DOI: 10.1016/S0021-9673(00)96972-3
16. Wyndham, K. D.; O’Gara, J. E.; Walter, T. H. et al. Characterization and Evaluation of C18 HPLC Stationary Phases Based on Ethyl-Bridged Hybrid Organic/Inorganic Particles
    Anal Chem 2003, 75 (23), 6781-6788. DOI: 10.1021/ac034767w
17. Dong, M. W.; Miller, G.; Paul, R. MS-Compatible ICH Impurity Analysis with a High-pH Mobile Phase. J Chromatogr A 2003, 987, 283-290. DOI: 10.1016/s0021-9673(02)01961-1
18. McCalley, D. V. Study of Overloading of Basic Drugs and Peptides in Reversed-Phase HPLC Using pH Adjustment of Weak Acid Mobile Phases Suitable for Mass Spectrometry. J Chromatogr A 2005, 1075 (1-2), 57-64. DOI: 10.1016/j.chroma.2005.02.090
19. Dong, M. W. A Universal Generic RPC Method for Pharma Analysis, LCGC North Am 2016, 34(6), 408-419.
20. Fountain, K. J., et al, Practical Applications of Charged Surface Hybrid (CSH), Waters Application Note 720003720, 2010.
21. Long, W. Use of Poroshell HPH-C18 Columns at Elevated pH as a Tool for Method Development, Agilent Application Note 5991-4893EN, 2014.

Download the PDF Here